{"id":403540,"date":"2020-12-21T08:03:14","date_gmt":"2020-12-21T13:03:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403540"},"modified":"2020-12-21T08:03:14","modified_gmt":"2020-12-21T13:03:14","slug":"the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/","title":{"rendered":"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancy<br \/><\/em><br \/>\n          \n        <\/li>\n<li style=\"margin-bottom:6pt\">\n          <em>EC approval is based on Phase 3 study data demonstrating that FINTEPLA safely and significantly reduced convulsive seizure frequency for Dravet syndrome patients whose seizures were not adequately controlled on existing medications, including stiripentol<\/em>\n        <\/li>\n<li style=\"margin-bottom:6pt\">\n          <em>First EU market launch planned for Germany in Q1 2021<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>EMERYVILLE, Calif., Dec.  21, 2020  (GLOBE NEWSWIRE) &#8212; Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has granted marketing authorization for FINTEPLA<sup>\u00ae<\/sup> (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. Dravet syndrome is a rare, lifelong epilepsy that begins in infancy and is marked by severe refractory seizures, frequent medical emergencies, significant cognitive and behavioral impairments, and an increased risk of sudden premature death (SUDEP).<\/p>\n<p>\u201cWe deeply appreciate the physicians and Dravet community whose support led to this important milestone,\u201d said Stephen J. Farr, Ph.D., President and CEO of Zogenix. \u201cWith the EC approval in place, we can now begin making FINTEPLA more widely available for the treatment of Dravet syndrome patients in Europe who seek new safe and effective treatment options.\u201d<\/p>\n<p>The EC\u2019s approval of FINTEPLA was based on positive safety and efficacy results from two randomized, international, multi-center, placebo-controlled Phase 3 trials (Study 1 and Study 2), as well as data from an interim analysis of a long-term, open-label extension study in 330 Dravet syndrome patients treated up to 3 years.<\/p>\n<p>\u201cAfter a healthy start in life, children with Dravet syndrome suffer from frequent and prolonged epileptic seizures, which determine the future of the child and mean that parents are on constant alert. Current treatments for Dravet syndrome are unsatisfactory, resulting in the disease affecting motor and mental development,\u201d said Dr. Tilman Polster, a pediatric epilepsy specialist at the Mara Hospital of the Bethel Epilepsy Centre in Bielefeld, Germany, and primary investigator for fenfluramine oral solution in Dravet syndrome in Germany. \u201cExperience from clinical studies has shown that FINTEPLA offers an impressive reduction in seizures, plus an improvement in quality of life. In conjunction with the ongoing data being collected on the safety profile of the therapy, FINTEPLA represents an effective new treatment option and an important hope for the families concerned.\u201d<\/p>\n<p>When added to other antiepileptic therapies, including stiripentol, FINTEPLA provided a highly statistically significant and clinically meaningful reduction in convulsive seizure frequency. The most commonly reported adverse events that occurred in patients treated with this included decreased appetite, diarrhea, pyrexia, fatigue, upper respiratory tract infection, lethargy, somnolence and bronchitis.<\/p>\n<p>With this approval, and subject to price and reimbursement being implemented according to national regulations, Zogenix will be able to market FINTEPLA in all European Union member countries, and in the United Kingdom, Norway, Iceland, and Liechtenstein.<\/p>\n<p>\n        <strong>Controlled Access Program<\/strong><br \/>\n        <br \/>FINTEPLA will be available in Europe under a controlled access program requested by the European Medicines Agency to prevent off-label use for weight management and to confirm that prescribing physicians have been informed of the need for periodic cardiac monitoring in patients taking FINTEPLA.<\/p>\n<p>Zogenix will also conduct the FINTEPLA Registry, an observational registry to provide data on long-term safety of FINTEPLA and frequency of echocardiographic monitoring in routine practice.<\/p>\n<p>Earlier this year, FINTEPLA was approved by the U.S. Food &amp; Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome in patients aged two years and older<em>. <\/em>In addition, Zogenix recently reported positive results of a third Phase 3 study of FINTEPLA in Dravet syndrome to support planned registration in Japan, which corroborated the highly statistically significant and clinically meaningful convulsive seizure reductions seen in earlier multinational Phase 3 studies. FINTEPLA is also being studied for the potential treatment of seizures associated with other rare epilepsies.<\/p>\n<p>\n        <strong>About\u202fDravet Syndrome<\/strong><br \/>\n        <br \/>Dravet syndrome is a rare, devastating and life-long form of epilepsy that generally begins in infancy and is marked by frequent, treatment-resistant seizures, significant developmental, motor, and behavioral impairments, and an increased risk of sudden unexpected death in epilepsy (SUDEP). Affecting one in 15,700 live births in the U.S. and approximately one in 20,000 to 40,000 live births in Europe, most patients follow a course of developmental delay with cognitive, motor and behavioral deficits that persist into adulthood. Dravet syndrome severely impacts quality of life for patients, families and caregivers due to the high physical, emotional, caregiving, and financial burden associated with the disease.<\/p>\n<p>\n        <strong>About Zogenix<\/strong><br \/>\n        <br \/>Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company\u2019s first rare disease therapy, FINTEPLA<sup>\u00ae<\/sup> (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency (being developed through its subsidiary Modis Therapeutics). Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for genetic rare epilepsies.<\/p>\n<p>\n        <strong>Forward-Looking Statement<\/strong>\n      <\/p>\n<p align=\"justify\">Zogenix\u202fcautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as \u201cbelieves,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cindicates,\u201d \u201cwill,\u201d \u201cintends,\u201d \u201cpotential,\u201d \u201csuggests,\u201d \u201cassuming,\u201d \u201cdesigned,\u201d and similar expressions are intended to identify forward-looking statements. These statements include the potential that fenfluramine oral solution will be an important new treatment option for Dravet syndrome patients; Zogenix\u2019s plans to commercialize fenfluramine in Europe, including the timing of the launch. These statements are based on Zogenix\u2019s current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by\u202fZogenix\u202fthat any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix\u2019s business, including, without limitation: Zogenix\u2019s ability to successfully launch FINTEPLA, including launching a controlled access program\u00a0implemented due to risks related to valvular heart disease and pulmonary arterial hypertension,\u00a0and the conduct of the FINTEPLA Registry, and the timing thereof; the COVID-19 pandemic may disrupt Zogenix\u2019s business operations, impairing the ability to commercialize FINTEPLA in Europe and Zogenix\u2019s ability to generate product revenue in Europe; Zogenix may not be successful in executing its sales and marketing strategy for the commercialization of FINTEPLA in Europe; unexpected adverse side effects or inadequate therapeutic efficacy of fenfluramine that could limit commercialization, or that could result in recalls or product liability claims; and other risks described in Zogenix\u2019s prior press releases as well as in public periodic filings with the\u202fU.S. Securities &amp; Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and\u202fZogenix\u202fundertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are\u00a0qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\n        <strong>CONTACTS:<\/strong>\n      <\/p>\n<p>\n        <strong>Zogenix<\/strong><br \/>\n        <br \/>Melinda Baker<br \/>Senior Director, Corporate Communications<br \/>+1 (510) 788-8732 |\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5HMkOOwSU0529FNHyf2LeBA4DQ7ue_AgQRRGwg5R5LUwyeYpFbCHl4sFO3rMJkGt3iBXoqBzyg8ntYZPM4y28x3aej__5LV_190F7kJ5MRo=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>corpcomms@zogenix.com<\/u><\/a><\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Brian Ritchie\u00a0<br \/>Managing Director,\u202fLifeSci Advisors LLC<br \/>+1 (212) 915-2578 |\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XiHXSTL5vsn8_8sx7EY-X-W5ffU2iHj97R00a-TE_sBJhWMmZRXdWUIYOB9FBYMqLELqWWLJUDspG-PWlRmXS_jeeoim_MHco4pE8BDlQyexzzfA2V0pVKzGZntBND2M\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>britchie@lifesciadvisors.com<\/u><\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>\n        <em><br \/>\n          <u>In Europe<\/u><br \/>\n        <\/em><br \/>\n        <em>:<\/em> Kerry Lloyd-Jones, Account Director, Porter Novelli<br \/>+44 (0) 7949 794 290 | <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uXJto7G0RFpXXKXrKKz2Qp1tGxLXkFco2PDfy8-UE84MM7h_FE33vGGiOB3X1nqmhLSAEW_Nx6ItkUn4G0PoDxpqIBYlJaGrynZyWl1L_26HtL2ojoqR22IGIwGSi4dYuOK96-5iBHNwj2vc1ZPgFw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">kerry.lloyd-jones@porternovelli.co.uk<\/a><br \/><em><u>In the US<\/u><\/em>: Stefanie Tuck, Vice President, Porter Novelli<br \/>+1 (978) 390-1394 | <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cxVLBVr9k7SIhMh85vdCt5QZI7f2Qb80l6vZNFGi_z1EkPt0JFTaOVceQYwRyxIuehoCInLzcvW_eQvq4oq6jhWg6arFqZFgMJKFJ4YgDLLW6KqPKCsJGNhjEZBNbWxj\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">stefanie.tuck@porternovelli.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/4e39a092-e84d-4b42-99ec-ee7a18786ebd\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancy EC approval is based on Phase 3 study data demonstrating that FINTEPLA safely and significantly reduced convulsive seizure frequency for Dravet syndrome patients whose seizures were not adequately controlled on existing medications, including stiripentol First EU market launch planned for Germany in Q1 2021 EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) &#8212; Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has granted marketing authorization for FINTEPLA\u00ae (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. Dravet syndrome &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403540","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancy EC approval is based on Phase 3 study data demonstrating that FINTEPLA safely and significantly reduced convulsive seizure frequency for Dravet syndrome patients whose seizures were not adequately controlled on existing medications, including stiripentol First EU market launch planned for Germany in Q1 2021 EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) &#8212; Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has granted marketing authorization for FINTEPLA\u00ae (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. Dravet syndrome &hellip; Continue reading &quot;The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T13:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome\",\"datePublished\":\"2020-12-21T13:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/\"},\"wordCount\":1291,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/\",\"name\":\"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==\",\"datePublished\":\"2020-12-21T13:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome - Market Newsdesk","og_description":"Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancy EC approval is based on Phase 3 study data demonstrating that FINTEPLA safely and significantly reduced convulsive seizure frequency for Dravet syndrome patients whose seizures were not adequately controlled on existing medications, including stiripentol First EU market launch planned for Germany in Q1 2021 EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) &#8212; Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has granted marketing authorization for FINTEPLA\u00ae (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. Dravet syndrome &hellip; Continue reading \"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T13:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome","datePublished":"2020-12-21T13:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/"},"wordCount":1291,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/","name":"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==","datePublished":"2020-12-21T13:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTA3NyMzODg5MDI1IzUwMDA2NzQ2MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-european-commission-approves-zogenixs-fintepla-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"The European Commission Approves Zogenix\u2019s FINTEPLA\u00ae (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403540"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403540\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}